Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Maraviroc (Celsentri) With Raltegravir and Darunavir/Ritonavir for the Treatment of Triple Class Failure in Adult HIV-1 Infected Patients (TERCETO)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified November 2009 by The Huesped Foundation.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
Pfizer
Information provided by:
The Huesped Foundation
ClinicalTrials.gov Identifier:
NCT01013987
First received: November 13, 2009
Last updated: February 9, 2010
Last verified: November 2009
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: No date given